Who Should Have Multigene Germline Testing for Hereditary Cancer?

Free first pagePublished by American Society of Clinical Oncology

THE TAKEAWAY

In the article that accompanies this editorial, Yurgelun et al16 reported on the development and validation of PREMMplus, a model which incorporates personal and family history to predict who might benefit from a germline multigene cancer panel test. PREMMplus has the potential to reduce the number of probands tested for germline variants in the 19 cancer predisposition genes evaluated, but studies in ethnically diverse populations are required before widespread implementation.

AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Who Should Have Multigene Germline Testing for Hereditary Cancer?

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

No potential conflicts of interest were reported.

留言 (0)

沒有登入
gif